Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results

被引：0

作者：

Fang, S. ^{[1
]}

Xu, T. ^{[1
]}

Liu, N. ^{[1
]}

Wang, X. Y. ^{[1
]}

Cheng, W. W. ^{[1
]}

Fang, H. H. ^{[1
]}

机构：

[1] Nanjing Chest Hosp, Affiliated Brain Hosp Nanjing Med Univ, Nanjing, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期

关键词：

aumolertinib; non-small-cell lung cancer; co-mutations;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP12.01-25

引用

页码：S650 / S650

页数：1

共 50 条

[1] Outcomes in patients with EGFR-mutant locally advanced or metastatic NSCLC co-mutations receiving aumolertinib as first-line treatment: A retrospective study
Cun, F. S.
Zhang, H.
ANNALS OF ONCOLOGY, 2022, 33 : S1586 - S1586
[2] Effect of De Novo Co-Mutations on Clinical Outcomes in Patients Receiving First-Line Osimertinib for EGFRMutated NSCLC
Sun, F.
Banwait, M. K.
Herrmann, A.
Piotrowska, Z.
Yun, K.
Bazhenova, L. A.
Wakelee, H. A.
Neal, J. W.
Das, M. S.
Ramchandran, K. J.
Roy, M.
Diehn, M.
Myall, N. J.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S196 - S197
[3] Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR plus NSCLC Patients: The Updated Results
Fang, S.
Xu, T.
Zhao, X.
Liu, N.
Wang, X.
Cheng, W.
Fang, H.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S671 - S671
[4] Apatinib Plus Icotinib as First-Line Therapy For EGFR Co-Mutations NSCLC in Chinese Patients: An Exploratory Study
Shang, Y.
Li, X.
Huo, R.
Ji, M.
Song, Z.
Liu, B.
Jia, Y.
Li, Y.
Jiao, J.
Shi, J.
Zhang, Y.
Chen, X.
Yao, M.
Zhang, X.
Zang, A.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S984 - S984
[5] Real-world data of first-line treatment with aumolertinib for elderly EGFR plus NSCLC patients
Zhang, H.
Cun, F. S.
ANNALS OF ONCOLOGY, 2022, 33 : S1586 - S1587
[6] Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib
Duan, J. C.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S652 - S652
[7] High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC
Fan, Y.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S422 - S422
[8] Study of anlotinib combined with icotinib as the first-line treatment in NSCLC patients harboring activating EGFR mutations: Updated results of ALTER-L004
Huang, D.
Zhong, D.
Zhang, C.
Zhang, Y.
Shang, Y.
Wang, L.
ANNALS OF ONCOLOGY, 2021, 32 : S969 - S969
[9] Optimal first-line therapy for NSCLC with EGFR mutations
Joel W. Neal
Lecia V. Sequist
Nature Reviews Clinical Oncology, 2010, 7 : 71 - 72
[10] Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
Yang, Zhengyu
Chen, Ya
Wang, Yanan
Wang, Shuyuan
Hu, Minjuan
Zhang, Bo
Han, Baohui
FRONTIERS IN ONCOLOGY, 2021, 11

← 1 2 3 4 5 →